LONDON – Apogenix GmbH announced better-than-expected results from the final analysis of its Phase II controlled study of APG101 in the second-line treatment of glioblastoma multiforme, reporting median progression-free survival of 19.7 weeks in the treated group compared to 10.8 weeks in the control arm.
LONDON – The discovery that some types of healthy brain cells release substances that can kill brain tumor cells by inducing the tumor cells to undergo cell death could point the way toward new therapies for brain tumors.
As expected, the FDA gave the green light last Thursday to Amarin Corp. plc's Vascepa (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG greater than or equal to 500 mg/dL) hypertriglyceridemia.
LONDON – The first gene therapy to be approved in a Western regulated market finally made it over the finishing line on Thursday when the European Medicines Agency (EMA) gave the nod to Glybera after considering the treatment for lipoprotein lipase deficiency (LPL) for the fourth time.
• Celgene International Sarl, of Boudry, Switzerland, a subsidiary of Celgene Corp., said it will request a re-examination of the negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) regarding Istodax (romidepsin) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).
DUBLIN, Ireland – Attempts to force through cuts to embryonic stem cell funding in the European Union's (EU) next five-year R&D program, due to get under way in 2014, will be strongly resisted, according to the EU Research Commissioner Máire Geoghegan-Quinn.
DUBLIN, Ireland – Now that the great carnival that is the Euroscience Open Forum (ESOF) has folded its tent and set a course for Copenhagen, Denmark, it is clear that the event – the biggest ever general scientific meeting in Ireland – marks a turning point in the country's maturing engagement with research.
LONDON – Cell therapy specialist Cell Medica Ltd. has raised £17 million (US$26.5 million) in a mixture of public and private funding, including a grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to be devoted to setting up manufacturing and running a clinical trial in the state.
LONDON – Long-awaited proposals to streamline the process of getting permission for multinational clinical trials – and halt the flight of clinical research from Europe – have been published by the European Commission.
RSS